Armas Pharmaceuticals Inc., a NJ based pharmaceutical marketing & distribution corporation, and Shilpa Medicare Limited, a Karnataka based pharmaceutical company, have announced a distribution partnership agreement. This agreement will encompass various generic oncology injectables and orals within the U.S. market. The first product, an oncology injectable, to be introduced in late October 2018, has an approximate market size of $116 million annually. Armas expects to launch additional oncology products through the 1st quarter of 2019, with a market size totaling more than $430 million annually.

“We are extremely pleased to have an opportunity to partner with Shilpa Medicare Limited, to provide to the US market quality oncology products. Our highly skilled team also looks forward to identifying products for development, utilizing alternative dosage forms, and delivery methods to improve the patient experience.”, says John Niemi, President & CEO of Armas.

“We are very excited about this partnership. The combination of Armas’ deep customer experience and Shilpa’s vertical integration, high quality development and manufacturing capabilities are well suited to launch our portfolio of products approved and under FDA review while providing affordable medicines to patients”, says Adam Levitt, CEO of Shilpa North America.